Circulating Tumor DNA as Biomarkers for CancerDetection

作     者：Xiao Han Junyun Wang Yingli Sun 

作者机构：CAS Key Laboratory of Genomic and Precision Medicine China Gastrointestinal Cancer Research Center Beijing Institute of Genomics Chinese Academy of Sciences Beijing 100101 China University of Chinese Academy of Sciences Beijing 100049 China 

出 版 物：《Genomics, Proteomics & Bioinformatics》 (基因组蛋白质组与生物信息学报（英文版）)

年 卷 期：2017年第15卷第2期

页      面：59-72页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 0714[理学-统计学（可授理学、经济学学位）] 0703[理学-化学] 0701[理学-数学] 10[医学] 0812[工学-计算机科学与技术（可授工学、理学学位）] 

基　　金：supported by the Precision Medicine Research Program of the Chinese Academy of Sciences (Grant No. KJZD-EW-L14) the National Basic Research Program of China (973 Program Grant Nos. 2012CB518302 and 2013CB911001) the National Natural Science Foundation of China (Grant Nos. 31540033 and 91019024) the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDA01040407) 

主　　题：Precision medicine Liquid biopsy Circulating tumor DNA Biomarker Clinical diagnosis Cell-free nucleic acids 

摘      要：Detection of circulating tumor DNAs(ct DNAs) in cancer patients is an important component of cancer precision medicine ct DNAs. Compared to the traditional physical and biochemical methods, blood-based ct DNA detection offers a non-invasive and easily accessible way for cancer diagnosis, prognostic determination, and guidance for treatment. While studies on this topic are currently underway, clinical translation of ct DNA detection in various types of cancers has been attracting much attention, due to the great potential of ct DNA as blood-based biomarkers for early diagnosis and treatment of cancers. ct DNAs are detected and tracked primarily based on tumorrelated genetic and epigenetic alterations. In this article, we reviewed the available studies on ct DNA detection and described the representative methods. We also discussed the current understanding of ct DNAs in cancer patients and their availability as potential biomarkers for clinical purposes. Considering the progress made and challenges involved in accurate detection of specific cell-free nucleic acids, ct DNAs hold promise to serve as biomarkers for cancer patients, and further validation is needed prior to their broad clinical use.